RNS Number : 0177G
LungLife AI, INC
15 November 2022
 

LungLife AI, Inc.

("LungLife" or the "Company")

 

Block Listing Six Monthly Return

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing:

 

Name of applicant:

LungLife AI, Inc.

Name of scheme:

1.    2010 Stock Incentive Plan

2.    2020 Stock Incentive Plan

3.    2021 Omnibus Long-Term Incentive Plan

Number and class of securities originally admitted:

1,356,139 common shares of US $0.0001 each

Date of admission:

15 November 2021

Period of return:

From:

15 May 2022

To:

15 November 2022

Balance of unallotted securities under scheme(s) from previous return:

1.    480,775

2.    201,374

3.    673,990

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1.    NIL

2.    NIL

3.    NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

1.    5,192

2.    NIL

3.    NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1.    475,583

2.    201,374

3.    673,990

 

 

Name of contact:

David Anderson, Chief Financial Officer

Telephone number of contact:

+44 (0)20 7933 8780 or lunglifeai@walbrookpr.com

 

 

For further information please contact:

 

LungLife AI, Inc.

www.lunglifeai.com

Paul Pagano, CEO 

Via Walbrook PR

David Anderson, CFO

 

 

 

Investec Bank plc (Nominated Adviser & Broker)

Tel: +44 (0)20 7597 5970

Daniel Adams / Virginia Bull / Cameron MacRitchie




Walbrook PR Limited

 Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com

Paul McManus / Alice Woodings / Phil Marriage

Mob: 07980 541 893 / 07407 804 654 / +44 07867 984 082

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRGPGUUGUPPGPU